[go: up one dir, main page]

LT3052080T - Ilgo veikimo spiro-izoksazolino vaistinės formos - Google Patents

Ilgo veikimo spiro-izoksazolino vaistinės formos

Info

Publication number
LT3052080T
LT3052080T LTEPPCT/US2014/057588T LTUS2014057588T LT3052080T LT 3052080 T LT3052080 T LT 3052080T LT US2014057588 T LTUS2014057588 T LT US2014057588T LT 3052080 T LT3052080 T LT 3052080T
Authority
LT
Lithuania
Prior art keywords
spiro
acting
long
isoxazoline
formulations
Prior art date
Application number
LTEPPCT/US2014/057588T
Other languages
English (en)
Inventor
Todd Foster
Laibin Luo
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of LT3052080T publication Critical patent/LT3052080T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LTEPPCT/US2014/057588T 2013-09-30 2014-09-26 Ilgo veikimo spiro-izoksazolino vaistinės formos LT3052080T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361884467P 2013-09-30 2013-09-30
PCT/US2014/057588 WO2015048371A1 (en) 2013-09-30 2014-09-26 Long-acting spiro-isoxazoline formulations

Publications (1)

Publication Number Publication Date
LT3052080T true LT3052080T (lt) 2025-08-25

Family

ID=51794952

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2014/057588T LT3052080T (lt) 2013-09-30 2014-09-26 Ilgo veikimo spiro-izoksazolino vaistinės formos

Country Status (19)

Country Link
US (1) US10350196B2 (lt)
EP (2) EP3052080B1 (lt)
JP (1) JP6209272B2 (lt)
CN (1) CN105579029B (lt)
AU (1) AU2014324837B2 (lt)
BR (1) BR112016006182B1 (lt)
CA (1) CA2924537C (lt)
DK (1) DK3052080T3 (lt)
ES (1) ES3038245T3 (lt)
FI (1) FI3052080T3 (lt)
HR (1) HRP20250874T1 (lt)
HU (1) HUE072454T2 (lt)
LT (1) LT3052080T (lt)
MX (1) MX374480B (lt)
PL (1) PL3052080T3 (lt)
PT (1) PT3052080T (lt)
RS (1) RS67084B1 (lt)
SI (1) SI3052080T1 (lt)
WO (1) WO2015048371A1 (lt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE072822T2 (hu) 2013-12-20 2025-12-28 Intervet Int Bv Izoxazolin kompozíciók és azok felhasználása parazita fertõzések megelõzésében vagy kezelésében állatokban
EP3280413A1 (en) * 2015-04-08 2018-02-14 Merial, Inc. Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof
WO2016207234A1 (en) 2015-06-23 2016-12-29 Intervet International B.V. Isoxazoline solution containing vitamin e for use with sanitized drinking water
UY37137A (es) * 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
IL297676B2 (en) 2016-03-25 2023-12-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
WO2017201134A1 (en) * 2016-05-20 2017-11-23 Avista Pharma Solutions, Inc. Synthetic process and novel intermediates
EP3525763B1 (en) 2016-10-12 2025-03-05 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
IL304026B2 (en) 2017-03-24 2024-11-01 Intra Cellular Therapies Inc A pharmaceutical preparation containing 1-(4-fluoro-phenyl)-4-((Sa10,Rb6)-3-D2-2,2-methyl-2, 3, a10, 10, 9, b6- hexahydro-H7, H1- Pyrido[3',4',:4,5]pyrrolo[3,2,1-de]quioxalin-8-yl)-butan-1-one and its uses
PH12020550555B1 (en) 2017-11-07 2024-03-06 Intervet Int Bv Injectable isoxazoline pharmaceutical compositions and uses thereof
UA127892C2 (uk) 2017-11-07 2024-02-07 Інтервет Інтернешнл Б.В. Спосіб одержання частинок ізоксазоліну великого розміру
AU2018385363B2 (en) * 2017-12-12 2024-06-13 Intervet International B.V. Implantable isoxazoline pharmaceutical compositions and uses thereof
AR113997A1 (es) 2017-12-21 2020-07-08 Intervet Int Bv Composiciones antiparasitarias para unción dorsal continua
CN110787661A (zh) * 2018-08-01 2020-02-14 台鉅生技股份有限公司 聚合物-胶原蛋白复合膜及其制造方法
WO2020047241A1 (en) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
CN109053751A (zh) * 2018-08-30 2018-12-21 成都海博锐药业有限公司 具有螺环结构的fxr调节剂
BR112021003655A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
CN118873536A (zh) 2018-08-31 2024-11-01 细胞内治疗公司 新方法
PH12021552713A1 (en) 2019-05-03 2022-07-04 Intervet Int Bv Injectable pharmaceutical compositions and uses thereof
DK4153133T3 (da) * 2020-05-20 2024-02-05 Intervet Int Bv Injicerbare farmaceutiske sammensætninger og anvendelser deraf
AU2021311722A1 (en) 2020-07-24 2023-02-02 Elanco Us Inc. Process for making an isoxazoline compound and intermediate thereof
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
JPS523342B2 (lt) 1972-01-26 1977-01-27
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
JPS6098823A (ja) 1983-11-02 1985-06-01 株式会社東芝 電力変換装置
US6136838A (en) * 1998-03-19 2000-10-24 Merck & Co., Inc. Sulfurpentafluorophenylpyrazoles for controlling ectoparasitic infestations
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
GB2386066A (en) * 2002-02-28 2003-09-10 Norbrook Lab Ltd Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US8362086B2 (en) * 2005-08-19 2013-01-29 Merial Limited Long acting injectable formulations
TW200846029A (en) * 2007-02-09 2008-12-01 Wyeth Corp High dose, long-acting ectoparasiticide for extended control
RU2578036C2 (ru) 2010-06-29 2016-03-20 Сева Санте Анимале Са Новые инъекционные композиции эприномектина
WO2012120399A1 (en) 2011-03-10 2012-09-13 Pfizer Inc. Spirocyclic isoxazoline derivatives as antiparasitic agents
BRPI1103229B1 (pt) 2011-07-18 2020-10-06 Universidade Federal Do Rio De Janeiro Composições farmacêuticas microparticuladas contendo antiparasitários para terapia subcutânea prolongada, uso das ditas composições farmacêuticas para a produção de um medicamento e método de tratamento de parasitoses

Also Published As

Publication number Publication date
EP3052080B1 (en) 2025-06-25
US10350196B2 (en) 2019-07-16
WO2015048371A1 (en) 2015-04-02
AU2014324837B2 (en) 2019-01-17
EP4628077A3 (en) 2025-12-31
JP2016536272A (ja) 2016-11-24
MX2016004035A (es) 2016-06-02
FI3052080T3 (fi) 2025-08-22
RS67084B1 (sr) 2025-09-30
BR112016006182A8 (pt) 2020-02-18
CA2924537A1 (en) 2015-04-02
US20160235720A1 (en) 2016-08-18
EP4628077A2 (en) 2025-10-08
PL3052080T3 (pl) 2025-10-20
AU2014324837A1 (en) 2016-03-17
DK3052080T3 (da) 2025-08-18
CA2924537C (en) 2018-01-16
JP6209272B2 (ja) 2017-10-04
HUE072454T2 (hu) 2025-11-28
ES3038245T3 (en) 2025-10-10
BR112016006182A2 (pt) 2017-08-01
MX374480B (es) 2025-03-06
EP3052080A1 (en) 2016-08-10
CN105579029A (zh) 2016-05-11
HRP20250874T1 (hr) 2025-09-26
PT3052080T (pt) 2025-08-22
HK1223270A1 (en) 2017-07-28
CN105579029B (zh) 2019-03-05
SI3052080T1 (sl) 2025-11-28
BR112016006182B1 (pt) 2023-01-10

Similar Documents

Publication Publication Date Title
IL279395A (en) A vaccine
SI3052080T1 (sl) Dolgo delujoče spiro-izoksazolinske formulacije
GB201319791D0 (en) Formulations
GB201304662D0 (en) Compositions
GB201321242D0 (en) Immunogenic compound
EP2964371A4 (en) SOLVENT FORMULATIONS
GB201319792D0 (en) Formulations
ZA201505830B (en) Formulations of organc compounds
IL245420A0 (en) New formulations
GB201320432D0 (en) Novel formulation
IL242493A0 (en) Pharmaceutical formulations relieve radioactivity
PL3082762T3 (pl) Kompozycje ketoprofenowe o długim działaniu
EP2968256A4 (en) Budiodarone formulations
PL3060256T3 (pl) Nowa stabilna formulacja
GB201322948D0 (en) Improved formulation
GB201317718D0 (en) Novel formulation
GB2510633B (en) Temporary pathway
GB2517232B (en) Formulation
EP2991632A4 (en) TIGECYCLINFORMULIERUNGEN
GB2508681B (en) Barrow
SG11201604136PA (en) Improved formulations for virosomes
GB201317717D0 (en) Novel formulation
EP2986109A4 (en) IMPROVED ECTOPARASITICIDE FORMULATIONS
GB201319352D0 (en) Formulation
GB201312347D0 (en) Formulation